Larimar Therapeutics (LRMR) Company Report

Larimar Therapeutics, Inc. entered into an underwriting agreement on February 25, 2026, for the issuance and sale of 20,000,000 firm shares of common stock at a public offering price of $5.00 per share.
The underwriters fully exercised their option to purchase an additional 3,000,000 shares on February 26, 2026, bringing the total shares sold to 23,000,000.
The company expects to receive approximately $107.6 million in net proceeds from the offering, after deducting underwriting discounts, commissions, and estimated offering expenses.
The offering is anticipated to close on February 27, 2026.

2 days ago

8-K

Larimar Therapeutics Announces Pricing of Upsized Public Offering

LRMR

Larimar Therapeutics, Inc. (Nasdaq: LRMR) announced the pricing of an upsized underwritten public offering of 20,000,000 shares of its common stock at $5.00 per share.
The offering is expected to generate aggregate gross proceeds of $100 million for Larimar, before deducting underwriting discounts and commissions and other offering expenses.
Larimar has granted the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of its common stock.
The net proceeds from the offering will be used to support the development of nomlabofusp and for working capital and general corporate purposes, including research and development and commercialization expenses.

3 days ago

Press Release

Larimar Therapeutics Announces Proposed Public Offering

LRMR

New Projects/Investments

Larimar Therapeutics has commenced an underwritten public offering to raise $75 million through the sale of common stock and pre-funded warrants.
The company expects to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of securities.
The net proceeds from the offering are intended to support the development of nomlabofusp and for working capital and general corporate purposes, including research and development and commercialization expenses.
J.P. Morgan and Guggenheim Securities are acting as joint bookrunning managers for the proposed offering.

3 days ago

Press Release

Larimar Therapeutics Receives FDA Breakthrough Therapy Designation

LRMR

Product Launch

New Projects/Investments

Larimar Therapeutics' nomlabofusp has been granted FDA Breakthrough Therapy Designation for the treatment of Friedreich’s ataxia, a designation that covers adults and children.
This designation is expected to expedite development and review, with a potential accelerated Biologics License Application (BLA) targeted for June 2026 and a potential commercial launch in the first half of 2027.
Following the announcement, Larimar's shares increased approximately 29–38% in premarket and intraday trading, with trading volume surging to 43.95 million shares.
Larimar remains a clinical-stage biotech company with no revenue and a negative EPS of -1.93.

4 days ago

Morningstar

Larimar Therapeutics Announces FDA Breakthrough Therapy Designation and Reiterates Planned BLA Submission

LRMR

Product Launch

New Projects/Investments

Larimar Therapeutics, Inc. (LRMR) announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to nomlabofusp for the treatment of adults and children with Friedreich's ataxia (FA).
The company reiterated its planned Biologics License Application (BLA) submission for nomlabofusp in June 2026, seeking accelerated approval, with a U.S. launch targeted for the first-half 2027 if approved.
The FDA has continued to align with the use of skin FXN as a novel surrogate endpoint to support the BLA submission and is aligned with plans for a global confirmatory Phase 3 study to be underway at the time of BLA submission.
Larimar Therapeutics estimates $136.9 million in cash and investments at December 31, 2025, providing a projected runway into Q4 2026.

4 days ago

8-K

Larimar Therapeutics Receives FDA Breakthrough Therapy Designation for Nomlabofusp and Confirms BLA Submission Timeline

LRMR

Product Launch

New Projects/Investments

Guidance Update

Larimar Therapeutics' nomlabofusp program has been granted Breakthrough Therapy Designation by the FDA for the treatment of adults and children with Friedreich's ataxia (FA).
The FDA has indicated continued alignment on considering skin FXN as a novel surrogate endpoint to support a planned Biologics License Application (BLA) submission for accelerated approval.
The company anticipates topline open-label study data in Q2 2026 and is on track for a BLA submission in June 2026.
A U.S. launch for nomlabofusp is targeted for the first-half 2027, pending approval.

4 days ago

Press Release

Larimar Therapeutics Announces Exchange of Common Stock for Series A Convertible Preferred Stock and Increase in Authorized Preferred Shares

LRMR

Convertible Preferred Issuance

Larimar Therapeutics, Inc. entered into an exchange agreement on January 21, 2026, with Blue Owl Healthcare Opportunities IV Public Investments LP, where the stockholder exchanged 2,500,000 shares of common stock for 250,000 shares of Series A convertible preferred stock.
Each share of Series A Convertible Preferred Stock is convertible into 10 shares of common stock and generally holds no voting rights, participating pari passu with common stock in liquidation.
In connection with this exchange, the company filed a Certificate of Amendment on January 21, 2026, to increase the authorized Series A Convertible Preferred Stock from 250,000 shares to 500,000 shares.
The exchange is anticipated to close on January 23, 2026.

Jan 22, 2026, 12:00 PM

8-K

Larimar Therapeutics Provides Update on Friedreich's Ataxia Program and Regulatory Timeline

LRMR

New Projects/Investments

Guidance Update

Product Launch

Larimar Therapeutics is developing nomlabofusp for Friedreich's ataxia (FA), a devastating neurodegenerative disease, aiming to be the first disease-modifying therapy by restoring frataxin levels.
The company plans to submit a Biologics License Application (BLA) in Q2 2026 for accelerated approval, using frataxin levels as a novel surrogate endpoint, with a targeted launch in early 2027.
Clinical data from the ongoing open-label study shows treated patients achieved frataxin levels above the 50% mark by day 180 and demonstrated an improvement of 2.25 points in mFARS, which is considered clinically meaningful.
While generally well-tolerated, seven patients experienced anaphylaxis, primarily early in treatment, which was treatable with standard therapy; mitigation strategies are in place.
A confirmatory Phase 3 trial for ambulatory patients (2-40 years old) is being initiated, with regulatory authorities having reviewed and approved the protocol.

Jan 14, 2026, 5:00 PM

Transcript

Larimar Therapeutics Provides Update on Friedreich's Ataxia Program

LRMR

Product Launch

New Projects/Investments

Larimar Therapeutics is developing nomlabofusp as a potential first disease-modifying therapy for Friedreich's ataxia (FA), a rare neurodegenerative disease caused by frataxin deficiency.
The company plans to submit a Biologics License Application (BLA) for accelerated approval in Q2 2026, targeting a launch in early 2027. The FDA has agreed to use frataxin levels as a novel surrogate endpoint for review.
Clinical data indicates that nomlabofusp led to an improvement of 2.25 points in mFARS, an outcome measure for FA, while a matched reference population worsened by one point. This improvement is considered clinically meaningful.
The safety profile includes common injection site reactions and seven cases of anaphylaxis among 65 exposed patients, all of which were treatable with EpiPens and resolved without long-term issues.
A confirmatory Phase III trial for 100-150 ambulatory patients is being initiated, with the first subject expected to be dosed early in 2026.

Jan 14, 2026, 5:00 PM

Transcript

Larimar Therapeutics Details Nomlabofusp Development and Regulatory Strategy

LRMR

Product Launch

New Projects/Investments

Guidance Update

Larimar Therapeutics is developing nomlabofusp for Friedreich's ataxia (FA), a rare neurodegenerative disease affecting approximately 5,000 patients in the US and 20,000 worldwide.
The company is pursuing accelerated approval for nomlabofusp, with a BLA filing in Q2 2026 based on frataxin levels as a novel surrogate endpoint, targeting a launch in early 2027. A regulatory update is also planned for Q1 2026.
Clinical data from an open-label study showed that treated patients achieved skin frataxin levels above the 50% mark by day 180 and demonstrated a 2.25-point improvement in mFARS score, considered clinically meaningful, compared to worsening in a natural history study.
While the most common adverse events are injection site reactions, seven patients experienced anaphylaxis which was treatable with EpiPens, and mitigation strategies are in place.
A Phase III confirmatory study is being initiated, enrolling 100-150 ambulatory patients for 18 months, with first dosing expected early in 2026.